© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
October 04, 2022
The hemophilia organization developed a shared decision-making tool for patients and providers.
Long-acting recombinant replacement factor gets favorable rating from multidisciplinary group. Gene therapy was viewed with some wariness.
October 03, 2022
Program in Hidalgo, Texas, cost less than $250 per family. A study found that the intervention saved each household an average of $36 per day.
October 02, 2022
A longitudinal study aims to identify which children with asthma are more likely to suffer a loss of lung function.
September 21, 2022
Findings suggest that screening people with hemophilia for diabetes and hypertension might have benefits.
September 19, 2022
An analysis found that a single dose of gene therapy would be more cost-effective than on-demand or prophylaxis factor replacement in 92% of cases.